Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Oleg Gluz,Matthias Christgen,Nadia Harbeck,Stefan Kraemer,Bahriye Aktas,Petra Krabisch,Benno Nuding,Marianne Just,Cornelia Liedtke,Steven Shak,Ulrike Nitz,Rachel Wuerstlein,Toralf Reimer,Sherko Kümmel,Christer Svedman,Andrea Stefek,Michael Clemens ,Fatemeh Lorenz-Salehi ,Hans Kreipe ,Ronald Kates

doi:10.1200/jco.2016.34.15_suppl.556

Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Oleg Gluz, Matthias Christgen + Show 18 more

https://doi.org/10.1200/jco.2016.34.15_suppl.556

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 4

Affiliation: Deutsches Archäologisches Institut, Zentrale, Hannover Medical School, Ludwig-Maximilians-Universität München, University Hospital Cologne, Essen University Hospital, Klinikum Chemnitz, Federal Highway Research Institute, Klinikum Bielefeld, Genomic Health (United States), Evangelisches Krankenhaus Bethesda Mönchengladbach, LMU Klinikum, University of Rostock, Kliniken Essen-Mitte, Johanniter-Krankenhaus Bonn, Klinikum Mutterhaus der Borromäerinnen, Helios Dr. Horst Schmidt Kliniken Wiesbaden, Ansys (Germany)

#Early Breast Cancer #21-gene Recurrence Score + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

556Background: The 21-gene Recurrence Score (RS) assay, nodal status, grade, and ER, PR, Ki67, or IHC4 are recommended for chemotherapy (CT) decision making in HR+/HER2- EBC. The phase III PlanB tr...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.